Results 151 to 160 of about 157,656 (310)

A critical appraisal of the safety of bedinvetmab (Beransa), a canine antinerve growth factor monoclonal antibody

open access: yesAustralian Veterinary Journal, EarlyView.
Clinical scenario Canine osteoarthritis (OA) is a degenerative joint disease and is one of the most common chronic conditions in dogs and other species. The management of OA remains a longstanding focus in veterinary medicine. Traditionally, nonsteroidal anti‐inflammatory drugs (NSAIDs) have been the first‐line treatment option for canine OA. Recently,
X Yang, P Macarthur
wiley   +1 more source

Laypeople's Views on the Narrative Identity and Societal Treatment of Genetically Modified People

open access: yesBioethics, EarlyView.
ABSTRACT Genome editing in human embryos could raise new ethical issues by changing future people's narrative and numerical identity. Most philosophers agree that some genetic modifications would have larger effects on identity than others, but they disagree on what criteria might explain these differences and have not supported their claims ...
Derek So, Yann Joly, Robert Sladek
wiley   +1 more source

Survey of Adrenal Insufficiency Management for Duchenne muscular dystrophy in Italy. [PDF]

open access: yesEndocrine
Tornese G   +6 more
europepmc   +1 more source

A muscular dystrophy associated with bi‐allelic LEMD2 variants: Expanding the genotype of nuclear envelopathies

open access: yesBrain Pathology, EarlyView.
Proteomics‐guided exome re‐analysis identifies bi‐allelic variants in the nuclear envelope LEMD2 gene, expanding its phenotypic spectrum. Created in BioRender. Pauper, M. (2026) https://BioRender.com/xamvo92.
Marc Pauper   +17 more
wiley   +1 more source

Disease burden in Serbian patients with facioscapulohumeral muscular dystrophy. [PDF]

open access: yesFront Neurol
Ralic B   +9 more
europepmc   +1 more source

Diaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The absence of the protein dystrophin in Duchenne muscular dystrophy (DMD) leads to progressive muscle weakness, failing regeneration and deregulation of nitric oxide (NO) signalling. We focused on L‐citrulline, a precursor of L‐arginine, required for NO production in muscle, which is reduced in dystrophic mdx muscle ...
Lisamaura Tulimiero   +14 more
wiley   +1 more source

Quantitative ultrasound assessment of Duchenne muscular dystrophy using edge detection analysis [PDF]

open access: yes, 2016
Aarnink   +30 more
core   +2 more sources

Whole Exome Sequencing for Romanian Patients With Neurodevelopmental Disorders Through an International Collaboration

open access: yesClinical Genetics, EarlyView.
Whole exome sequencing for Romanian patients with neurodevelopmental disorders through an international collaboration—this study has provided a 50% diagnostic yield for patients with NDDs (27 positive results from 54 patients), supporting the implementation of a WES analysis that can identify SNVs, small INDELs, CNVs, and mitochondrial variants ...
Alexandru Caramizaru   +16 more
wiley   +1 more source

Metabolic Complications and Ultrasound-Detected Liver Abnormalities in Paediatric Patients With Duchenne Muscular Dystrophy. [PDF]

open access: yesPediatr Obes
Śledzińska K   +14 more
europepmc   +1 more source

Molecular Basis and Clinical Spectrum of WNT10A‐Related Oligodontia

open access: yesClinical Genetics, EarlyView.
Cellular Mechanism behind WNT10A phenotypes. ABSTRACT WNT10A mutations, a major genetic determinant of dental agenesis and ectodermal dysplasia, exert profound effects on craniofacial development. Although classified as rare disorders, these mutations account for more than half of oligodontia cases, reflecting their critical role.
Perennes Elise   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy